Delivery Order SPE2DR25D3103-SPE2DR26F0A1B
- Not listed
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $31,317.04 by the Defense Logistics Agency (DLA) on January 23, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector pharmaceutical product. The contract is firm fixed-price with no set-aside designation and is scheduled for completion by January 26, 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $7,258.92 by the Defense Logistics Agency (DLA) on January 13, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. Performance will be completed at the awardee's location in Conshohocken, Pennsylvania, with an ultimate completion date of January 14,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,880.79 by the Defense Logistics Agency on November 3, 2025, with an ultimate completion date of November 4, 2025. The contract, issued under a firm fixed price arrangement, covers the supply of Repatha 140 mg/ml SureClick auto-injectors. This delivery order was competitively awarded with no set-aside designation and represents a child award...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on May 30, 2025, for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, valued at $1,083.05, represents a competitively awarded contract with no set-aside designation and an ultimate completion date of June 2, 2025. The place of performance is located at the vendor's corporate office in...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order valued at $3,433.78 from the Defense Logistics Agency (DLA) on January 6, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be completed at the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of January 7, 2026. This delivery order...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a $6,497.25 delivery order by the Defense Logistics Agency on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is non-competitive and structured as a firm fixed-price delivery order with an ultimate completion date of January 22, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under Amerisourcebergen's...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on January 23, 2026, for Repatha 140 mg/ml SureClick auto-injector medication. The competitively awarded, firm fixed-price delivery order has a ceiling value of $13,018.84 and an ultimate completion date of January 26, 2026. This award carries no set-aside designation, indicating the contract was competed on a full and open...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,971.95 firm fixed-price delivery order from the Defense Logistics Agency on January 15, 2026, for Repatha 140 mg/ml SureClick auto-injectors. The award is unset-aside and competitively awarded, with an ultimate completion date of January 16, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract...
- Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) was awarded a delivery order valued at $12,175.92 on January 12, 2026, by the Defense Logistics Agency for the supply of Repatha 140 mg/mL SureClick auto-injectors. This non-competitive, firm fixed-price delivery order is expected to be completed by January 13, 2026, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order issued under Amerisourcebergen's larger...
- AmerisourceBergen Drug Corp was awarded a $7,085.19 delivery order by the Defense Logistics Agency (DLA) on May 30, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector medication. This is a firm fixed price, non-competitive delivery order with an ultimate completion date of June 2, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F0A1BDelivery Order
Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 23, 2026, for Repatha 140 mg/ml SureClick auto-injectors, valued at $5,758.55. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 26, 2026. The place of performance is Conshohocken, Pennsylvania, where Amerisourcebergen maintains its corporate headquarters. This delivery order is issued under Amerisourcebergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, Amerisourcebergen supplies a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. The Repatha delivery supports DLA's mission to provide critical pharmaceutical commodities, including specialty medications and biologics, to military treatment facilities and other federal healthcare institutions worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 1/22/26 |